^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | azercabtagene zapreleucel (PBCAR0191) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Title:
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy
Published date:
08/19/2020
Excerpt:
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor (CAR T) cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia (B-ALL).
